GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » Cash And Cash Equivalents

Orion Infusions (DHA:ORIONINFU) Cash And Cash Equivalents : BDT16.3 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Orion Infusions Cash And Cash Equivalents?

Orion Infusions's quarterly cash and cash equivalents declined from Jun. 2023 (BDT44.99 Mil) to Sep. 2023 (BDT32.18 Mil) but then stayed the same from Sep. 2023 (BDT32.18 Mil) to Dec. 2023 (BDT16.25 Mil).

Orion Infusions's annual cash and cash equivalents increased from Jun. 2021 (BDT10.35 Mil) to Jun. 2022 (BDT32.57 Mil) and increased from Jun. 2022 (BDT32.57 Mil) to Jun. 2023 (BDT44.99 Mil).


Orion Infusions Cash And Cash Equivalents Historical Data

The historical data trend for Orion Infusions's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions Cash And Cash Equivalents Chart

Orion Infusions Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.20 11.91 10.35 32.57 44.99

Orion Infusions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.30 19.19 44.99 32.18 16.25

Orion Infusions Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Orion Infusions  (DHA:ORIONINFU) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Orion Infusions Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Orion Infusions's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions (DHA:ORIONINFU) Business Description

Traded in Other Exchanges
N/A
Address
Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines